Home / Europa / Nederland / Life Sciences & Healthcare

Life Sciences & Healthcare

Ons toegewijde Life Sciences & Healthcare team is gespecialiseerd in het adviseren van cliënten uit de farmaceutische industrie, medische hulpmiddelen, cosmetica, novel food en agri.

Wij hebben ruime ervaring in het bedienen van onze  cliënten, die samen 80% van de meest toonaangevende spelers uit de sector beslaan. Omdat velen van ons in-house ervaring hebben, begrijpen wij uw unieke uitdagingen en behoeften en zijn wij in staat om u hands-on commercieel advies te geven.

Ons team is actief in alle relevante juridische disciplines die betrokken zijn bij de ondersteuning van deze sector. Dit omvat sectorspecifiek regulatory- en compliance-werk, intellectuele eigendomskwesties en mededingingsrechtelijk advies. Verder geven wij ook advies over commerciële contracten, data privacy, arbeidsrecht, onroerend goed en ondernemingsrecht. Dankzij onze expertise kunnen wij voorzien in zowel de lokale als internationale behoeftes van onze cliënten.

Their litigation abilities are excellent, with in-firm expertise available on related legal topics.

The Legal500 EMEA, 2022

Clients particularly value the team's commercial awareness, praising their "good insights into what is going on in the pharmaceutical market in the Netherlands."

Chambers Europe, 2022

The team is recommended for its "specific knowledge regarding tenders and projects in the field of medical appliances."

Chambers Europe 2021

The firm has "an excellent knowledge of pharmaceutical regulations and a practical mindset."

Chambers Europe 2021

‘Speedy responses and practical advice in pharma and corporate law matters.’

The Legal 500 EMEA, 2020

"really brilliant" , "broad network" and that the firm "co-ordinates things well".

Chambers Europe-wide, 2020

"Really efficient and quick."

Chambers Global, 2020

"The firm is a reliable international firm that has shown us a deep knowledge of the applicable law and significant practical experience on relevant cases."

Chambers Global, 2020

Their litigation abilities are excellent, with in-firm expertise available on related legal topics.

The Legal500 EMEA, 2022

Clients particularly value the team's commercial awareness, praising their "good insights into what is going on in the pharmaceutical market in the Netherlands."

Chambers Europe, 2022

The team is recommended for its "specific knowledge regarding tenders and projects in the field of medical appliances."

Chambers Europe 2021

The firm has "an excellent knowledge of pharmaceutical regulations and a practical mindset."

Chambers Europe 2021

‘Speedy responses and practical advice in pharma and corporate law matters.’

The Legal 500 EMEA, 2020

"really brilliant" , "broad network" and that the firm "co-ordinates things well".

Chambers Europe-wide, 2020

"Really efficient and quick."

Chambers Global, 2020

"The firm is a reliable international firm that has shown us a deep knowledge of the applicable law and significant practical experience on relevant cases."

Chambers Global, 2020

Selecteer een gebied

E-He­alth
Met tech­no­lo­gie en di­gi­ta­le in­no­va­tie als speer­punt van  in­no­va­tie  in de li­fe sci­en­ces en de zorg­sec­tor, ver­leg­gen be­drij­ven voort­du­rend&nb
Lees meer
Me­di­cal De­vi­ces and Dia­gnos­tics
De me­di­sche hulp­mid­de­len sec­tor ont­wik­kelt zich snel, waar­bij in­no­va­tie­ve, tech­ni­sche op­los­sin­gen wor­den geïnte­greerd en steeds gro­te­re hoe­veel­he
Lees meer
No­vel Food (in­cl. Can­na­bis/CBD)
Voor­beel­den van nieu­we voe­dings­mid­de­len zijn pro­duc­ten uit nieu­we bron­nen of die zijn ge­maakt met be­hulp van nieu­we pro­ces­sen. Denk maar aan mo­der­ne b
Lees meer
microscope with bottles of chemicals in forefront
Phar­ma­ceu­ti­cals
Het wordt steeds in­ge­wik­kel­der en duur­der om voor ge­nees­mid­de­len mar­ke­ting au­to­ri­sa­tie te krij­gen. Bo­ven­dien wordt vast­stel­ling van prijs en ver­goe­din
Lees meer
18/05/2023
CMS Li­fe Sci­en­ces & He­al­th­ca­re Glo­bal Bro­chu­re
With big deals fu­el­ling re­cord le­vels of M&A ac­ti­vi­ty, a stea­dy stream of in­no­va­ti­ve and dis­rup­ti­ve tech­no­lo­gies, new and in­cre­a­sin­gly com­plex re­gu­la­to­ry chal­len­ges and a thriving start-up com­mu­ni­ty...
Brochure
Sub­scri­be to Li­fe Sci­en­ces & He­al­th­ca­re to­pics

Feed

05/2023
CMS Li­fe Sci­en­ces & He­al­th­ca­re Glo­bal Bro­chu­re
With big deals fu­el­ling re­cord le­vels of M&A ac­ti­vi­ty, a stea­dy stream of in­no­va­ti­ve and dis­rup­ti­ve tech­no­lo­gies, new and in­cre­a­sin­gly com­plex re­gu­la­to­ry chal­len­ges and a thriving start-up com­mu­ni­ty...
Brochure
16/05/2023
Can­na­bis law and le­gis­la­ti­on in the Ne­ther­lands
Me­di­cal use The Dut­ch Opi­um Act dis­tin­guis­hes drugs with a low risk of harm (‘soft drugs’) from drugs with a high risk of harm (‘hard drugs’). Can­na­bis is li­sted un­der the soft drugs ca­te­go­ry...
Expert Guide Life Sciences & Healthcare
12/05/2023
Con­sulta­ti­on on the EU’s in­te­rim emis­si­ons re­duc­ti­on tar­get for 2040
Un­til 24 Ju­ne 2023 the Eu­ro­pean Com­mis­si­on is con­sul­ting to ga­ther views on the EU’s cli­ma­te tar­get for 2040.Sin­ce the Com­mu­ni­ca­ti­on of the Eu­ro­pean Green Deal in la­te 2019, the­re ha­ve been a raft of...
Law-Now Energy & Climate Change
10/05/2023
At last: in­va­li­di­ty and re­vo­ca­ti­on ac­ti­ons now avai­la­ble be­fo­re TM of­fi­ces...
One of the most sig­ni­fi­cant in­no­va­ti­ons in­tro­du­ced by the EU Tra­de Mark Di­rec­ti­ve 2015/2436 (the so-cal­l­ed tra­de mark re­form pack­a­ge) was the re­qui­re­ment for all EU coun­tries to im­ple­ment – whe­re not...
Law-Now Energy & Climate Change
04/05/2023
Di­gi­tal he­alth apps and te­le­me­di­ci­ne in the Ne­ther­lands
Di­gi­tal He­alth Apps/Soft­wa­re 1. How is the soft­wa­re within di­gi­tal he­alth apps clas­si­fied in your ju­ris­dic­ti­on, and what re­gu­la­ti­on(s) ap­ply? The re­le­vant le­gis­la­ti­on is the “Wet op de me­di­sche hulp­mid­de­len...
Expert Guide Life Sciences & Healthcare
Comparable
02/05/2023
CMS up­da­tes Ex­pert Gui­de on can­na­bis law and le­gis­la­ti­on
CMS Ex­pert Gui­de on can­na­bis law and le­gis­la­ti­on gi­ves sta­ke­hol­ders de­tai­led and up­da­ted in­for­ma­ti­on on the la­test de­vel­op­ments in can­na­bis re­gu­la­ti­on in key mar­kets. The Gui­de now co­vers two new ju­ris­dic­ti­ons:...
Law-Now Life Sciences & Healthcare
04/04/2023
Eu­ro­pean Com­mis­si­on amends Ar­ti­cle 102 TFEU guid­an­ce pa­per and an­noun­ces...
In 2008, the Com­mis­si­on adop­ted its Guid­an­ce on the Com­mis­si­on`s en­for­ce­ment pri­o­ri­ties in ap­ply­ing Ar­ti­cle 82 of the EC Tre­a­ty (now Ar­ti­cle 102 TFEU) to abu­si­ve ex­clu­si­o­na­ry con­duct by do­mi­nant un­der­ta­kings...
Law-Now Energy & Climate Change
03/04/2023
Ri­gorous Eu­ro­pean le­gis­la­ti­on brin­ging cla­ri­ty on pro­per green com­mu­ni­ca­ti­on
En­vi­ron­men­tal awa­re­ness and sustai­na­bi­li­ty ha­ve been sub­jects of in­ten­se dis­cus­si­ons sin­ce they are of gro­wing im­por­tan­ce to in­di­vi­du­als in their dai­ly de­ci­si­ons. Be­cau­se this di­men­si­on of eco­no­mic com­pe­ti­ti­on...
Law-Now Consumer Products
28/03/2023
Eu­ro­pean Par­li­a­ment and Coun­cil rea­dy to start ne­go­ti­a­ti­ons on EU Da­ta...
In Fe­bru­a­ry 2022 the Eu­ro­pean Com­mis­si­on pre­sen­ted its pro­po­sal for the EU Da­ta Act, which – if adop­ted - will in­tro­du­ce a far-rea­ching legal re­gime on ac­cess to and use of non-per­so­nal da­ta in the...
Law-Now Energy & Climate Change
24/03/2023
Li­fe Sci­en­ces & He­al­th­ca­re up­da­te: maart 2023
De con­ti­nue ont­wik­ke­ling van nieu­we me­di­sche hulp­mid­de­len en ge­nees­mid­de­len gaat ge­paard met een toe­ne­men­de rol van tech­no­lo­gie en ver­an­de­ren­de re­gel­ge­ving. In de ener­ve­ren­de li­fe sci­en­ces bran­che neemt de be­hoef­te aan spe­ci­a­lis­ti­sche ju­ri­di­sche ken­nis zo­doen­de steeds meer toe. Om u te hel­pen voor­op te blij­ven lo­pen, bren­gen wij daar­om een maan­de­lijk­se news­flash met de laat­ste ge­rech­te­lij­ke uit­spra­ken, in­for­ma­tie af­kom­stig van de au­to­ri­tei­ten en re­le­van­te ach­ter­grond­ar­ti­ke­len.Om na­vi­ge­ren zo een­vou­dig mo­ge­lijk te ma­ken, heb­ben we de in­for­ma­tie op­ge­splitst in twee over­zich­ten, één over­zicht spe­ci­fiek over ge­nees­mid­de­len en één over­zicht spe­ci­fiek over me­di­sche hulp­mid­de­len. Klik hier­on­der op het voor u re­le­van­te over­zicht en blijf op de hoog­te van de­ze cru­ci­a­le ont­wik­ke­lin­gen.
Publicaties
20/03/2023
Out with the old, in with the new? Con­si­de­ra­ti­ons for pa­ten­tees in op­ting...
So far in this se­ries of blog posts, we be­gan with an ar­ti­cle that high­ligh­ted so­me of the key chan­ges bet­ween the cur­rent Eu­ro­pean sy­s­tem of pa­tent pro­se­cu­ti­on and en­for­ce­ment and the new Uni­ta­ry Pa­tent...
Law-Now Energy & Climate Change
16/03/2023
Mer­ger con­trol re­view be­low fi­ling thres­holds – the ECJ To­wer­cast ju­dg­ment...
On 16 March 2023, the ECJ de­ci­ded that a M&A trans­ac­ti­on, which was not sub­ject to ex-an­te EU mer­ger con­trol, can be re­vie­wed – from an ex post per­spec­ti­ve – as to whe­ther the ac­qui­rer (through the...
Law-Now Energy & Climate Change
Laad meer artikelen